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Abstract 
Mineralocorticoid receptor (MR)contributes to retinal/choroidal homeostasis. Excess MR activation 
has been shown to be involved in pathogenesis of central serous chorioretinopathy (CSCR). Systemic 
administration of MR antagonist (MRA) reduces subretinal fluid and choroidal vasodilation, and 
improves the visual acuity in CSCR patients. To achieve long term beneficial effects in the eye while 
avoiding systemic side-effects, we propose the use ofbiodegradable spironolactone-loaded poly-
lactic-co-glycolic acid (PLGA)microspheres (MSs). In this work we have evaluated the ocular tolerance 
of MSs containing spironolactone in rats’ eyes. As previous step, we have also studied the tolerance 
of the commercial solution of canrenoate salt, active metabolite of spironolactone. PLGA MSs 
allowed in vitro sustained release of spironolactone for 30 days. Rat eyes injected with high 
intravitreous concentration of PLGA MSs (10 mg/mL) unloaded and loade d with spironolactone 
maintained intact retinal lamination at 1 month. However enhanced glial fibrillary acidic protein 
immunostaining and activated microglia/macrophages witness retinal stress were observed. ERG also 
showed impaired photoreceptor function. Intravitreous PLGA MSs concentration of 2 mg/mL 
unloaded and loaded with spironolactone resulted well tolerated. We observed reduced 
microglial/macrophage activation in rat retina compared to high concentration of MSs with normal 
retinal function according to ERG. Spironolactone released from low concentration of MSs was active 
in the rat retina. Low concentration of spironolactone-loaded PLGA MSs could be a safe therapeutic 
choice for chorioretinal disorders in which illicit MR activation could be  pathogenic. 
Keywords: Mineralocorticoid receptor, spironolactone, microspheres intraocular tolerance, Poly 
lactic-co-glycolic acid (PLGA), in vivo electroretinography, in vivo optical coherence tomography, 
immunohistochemistry 
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Introduction 
 
Mineralocorticoid receptor (MR), the ancestor corticoid receptor is expressed in the distal nephron 
where it regulates sodium and fluid reabsorption, modulating blood volume and arterial pressure. 
More recently, MR was evidenced in heart, blood vessels, brain, adipose tissue, skin and 
macrophages, recognized as non-classical mineralocorticoid targets [1, 2]. Illicit activation of MR has 
been demonstrated to induce inflammation, oxidative stress, fibrosis, hypertrophic remodelling and 
endothelial dysfunction and increasing evidences suggest the MR antagonism has therapeutic value 
for endothelial dysfunction, atherosclerosis, hypertension, heart failure and chronic kidney disease[3-
5].  
Spironolactone has been the first steroidal competitive MR antagonist drug (MRA) approved for the 
treatment of hypertension half a century ago. It is a potent but low-specific MRA, interacting at high 
dose with androgen receptors, and causing subsequent dose-dependent hormonal side-effects 
[6].Eplerenone, less potent but more specific RA, designed to reduce the hormonal effects of 
spironolactone, was approved by the Food and Drug Administration in 2002 for the prevention of 
cardiac complications after myocardial infarction and ventricular dysfunction[7, 8].  Both MRA can 
potentially induce hyperkalemia, particularly with impaired renal function.  
The eye is also a mineralocorticoid sensitive organ, expressing MR and pre-receptoral enzyme 11β-
hydroxysteroid dehydrogenase type 2 in the iris/ciliary body, neuroretina, retinal pigment epithelium 
and endothelial cells [9-13]. MR activation contributes to retinal fluid homeostasis through regulation 
of specific ion and water channels in retinal macroglial cells (Kir4.1 and AQP4) [9, 14].  An over-
activation of MR by excess glucocorticoid or endogenous activation has been hypothesized in the 
pathogenesis of central serous chorioretinopathy (CSCR) [11]. Systemic administration of MRA have 
effect on subretinal fluid and choroidal vasodilation, and improves the visual acuity in CSCR patients 
[11, 15-18].  Since our first studies, more than 15 clinical studies have confirmed that MRA reduces 
subretinal fluid associated with CSCR. However, to achieve and to further maintain therapeutic effect, 
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long-term use of MRA may be required[18], increasing the risk of side-effects. Spironolactone, 40-
fold more potent MRA than eplerenone, is associated on the long-term with hormonal side effects 
such as gynecomastia, erectile dysfunction and menstrual irregularities [6], being particularly bad 
tolerated in the CSCR population consisting mostly of middle-aged men. Although the ocular 
bioavailability of spironolactone and eplerenone after systemic administration has not been 
specifically studied, it is known that spironolactone induces the expression of the P-glycoprotein, a 
drug efflux protein that regulates the blood-brain barrier, and is one of its ligands [19], which may 
limit its ocular bioavailability. 
In order to avoid systemic undesirable effects and ensure optimized MR blockade, intraocular local 
MRA delivery is desired and sustained release drug delivery system is mandatory to avoid repeated 
intraocular injections. For preclinical development in animal models and for potential clinical 
development, we have chosen to prepare biodegradable microspheres (MSs)  using poly-lactic-co-
glycolic acid (PLGA) to provide a controlled delivery of the drug in a long fashion. Particle size can be 
reduced to allow injection of a suspension through a regular 30G needle and provide the sustained 
release of active products[20-22].PLGA, approved by FDA and the European Medical Agency for 
intraocular use[23, 24], is progressively hydrolysed in its monomers (lactic acid and glycolic acid), and 
subsequently converted into CO2 and water via Kreb’s cycle. Biodegradation in PLGA microspheres is 
described to occur in the polymeric matrix through a homogeneous hydrolytic chain cleavage 
mechanism leading to a sustained release of the active compounds included in the polymeric matrix 
[23, 24]. 
Intraocular tolerance of controlled drug delivery systems is critical as they are proposed for long term 
treatments. As the device is formed by a biomaterial and the active substance, it is also important to 
evaluate the in vivo response of the unloaded system. In the present work, spironolactone-loaded 
MSs releasing the drug in vitro for at least 30 days, were screened for anatomical and functional 
tolerance in normal rat eyes. In vivo and ex vivo tolerance analyses were performed 4 weeks after 
intravitreal injection of low and high amounts of microspheres in rats (0.1 mg and 0.5 mg, final 
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concentration in the rats vitreous of 2 and 10 mg/mL respectively). As the development of a novel 
controlled release also requires tolerance studies of the active molecule it self in the target tissue, we 
alsoevaluated the intraocular tolerance of an intravenous comercial solution of canrenoate salt 
(Soludactone), one of the active metabolites of spironolactone. To our knowledge the intraocular 
tolerance of spironolactone and its metabolites has not been previously studied. 
 
Material and Methods 
 
Animals 
All experiments were performed in accordance with the European Communities Council Directive 
86/609/EEC and approved by local ethical committees (Ce5/2012/113 andApproval VD2928). Adult 
male Wistar rats (8 weeks old) from Janvier breeding Center (Le Genest-Saint-Isle, France) or Charles-
River (L’Arbresle, France) were used. Animals were kept in pathogen-free conditions with food, water 
and litter and housed in a 12-hour light/12-hour dark cycle. Anesthesia was induced by intramuscular 
ketamine (40 mg/kg) and xylazine (4 mg/kg). Animals were sacrificed by carbon dioxide inhalation. 
 
Intravitreous injection of soludactone 
Intravitreous injections (IVT) were performed using microfine (300 μL) syringes with 30G needles 
under topical anesthesia (tetracaine 1%, Aldrich, Lyon, France). Five µL of the Soludactone® solution 
(Pfizer, Paris, France) at 37 µg/µL (final concentration in the vitreous: 10 µM) was injected in the rat 
eyes. Control rats received 5 µL of 0.9% NaCl. Soludactone® contains trometamol and water as 
excipients. Trometamol containing preparations have alreadybeen injected in the vitreous of animals 
and humans without any detectable toxicity[25, 26].We thus chose Soludactone® because it is a 
medical grade, commercialized product that could potentially be used for intraocular use in further 
clinical studies.  
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In vivo and histological analyses for rats injected with soludactone 
These experiments were performed in collaboration with department of ophthalmology of the 
University of Lausanne. One week after intravitreous Soludactone injection, rat retinal morphology 
was examined in vivo using a spectral domain optical coherence tomography (SD-OCT) system 
adapted for rat eyes (Bioptigen, Leica Microsystems, Buffalo Grove, IL, USA), and a retinal camera 
specially designed for mouse/rat retinal imaging (Micron III, Phoenix Research Labs, USA).  
Visual function of rat eyes was also evaluated 1 week after IVT using electro-retinography (ERG). 
ERGs were performed using Espion E2 system from Diagnosys LLC (Lowell, MA, USA). Animals were 
dark adapted overnight. Scotopic ERGs were performed in the dark with light intensities of flashes 
ranging from 0.0001 to 30 cd.s/m2. For photopic recordings, animals were light adapted for 5 min 
and then the response to light intensities of flashes ranging from 0.1 to 30 cd.s/m 2 were recorded. 
ERG records were analyzed using 2-way ANOVA and multiple t tests. Statistical significance was 
determined using the Holm-Sidak method, with alpha=5%. Each row was analyzed individually, 
without assuming a consistent SD. 
Rats were then sacrificed, each eye was dipped in Bouin’s solution for 24 hours, embedded in 
paraffin, cut in 4.5 m thick sections, and stained with haematoxylin - eosin. Sections through the 
optic nerve and through the injection site were analyzed under a microscope 
(Zeiss,Oberkochen,Germany) associated with a digital camera. 
 
In vitro stability of spironolactone in the presence of human vitreous 
An isotonic formulation of spironolactone was prepared using 0.9% NaCl  at a concentration of 6.2 
µM (2.6µg/mL). To determine whether spironolactone is stable when in contact with vitreous, 100 µL 
of spironolactone-containing formulation were added and mixed with 500 µL human vitreous and 
kept in room temperature. Fifty µL of vitreous sample were harvested at each time point at 0, 5, 10, 
30 and 60 minutes, then diluted with 25 µL acetonitrile containing ISTD, filtrated and analysed using 
Waters AcquityUPLC system (Saint-Quentin-en-Yvelines, France).  Experiments were performed in 
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triplicate. Kinetics of spironolactone concentration over time was established with reference to time 
0 considered as 100%.  
 
In vivo kinetics of spironolactone in rat eye 
Five µL of spironolactone formulation at concentration of 5 µM in 0.9% NaCl  (2.07 µg/mL) were 
injected in rat eyes. At 15, 30 and 60 minutes after IVT, intravitreal liquid was harvested. Twenty µL 
of each sample were diluted with 10 µL of acetonitrile containing ISTD and analysed using Water 
Acquity UPLC system. (n=4 eyes / time point).  
To evaluate ocular bioavailability after intravenous injection, 100 µL of 5 µM spironolactone (2.07 
µg/mL) was administrated in 6 rats. Eyes were enucleated at 15, 30 and 60 minutes after injection 
and vitreous/ aqueous humor were analysed for the presence of spironolactone or its metabolites. 
 
Preparation of blank and spironolactone-loaded PLGA Microspheres 
PLGA ratio 50:50 (Resomer®503) was acquired from BoehringerIngelheimPharma GmbH & Co. 
(Ingelheim, Germany). Spironolactone(Spiro) was obtained from Sigma-Aldrich (Schnelldorf, Germany) 
and Polyvinyl alcohol 72,000 g/mol (PVA) from Merck KGaA (Darmstadt, Germany). All organic 
solvents were HPLC grade and used as received.  
Spironolactone-loaded PLGA microspheres (MSs) were manufactured using an oil-in-water (O/W) 
emulsion solvent evaporation technique. Briefly, The O-phase was prepared with spironolactone (40 
mg) in 1 mL of PLGA dissolved in methylene chloride (20% w/v); Spiro:PLGA ratio of 2:10. This oily 
phase was emulsified with an aqueous solution composed by 5mL of PVA MilliQ® water solution (2% 
w/v). The emulsification procedure was performed at 5,000 rpm (1 min)  (Polytron® RECO, Kinematica 
GmbH PT 10-35, Lucerna, Switzerland). This O/W emulsion was subsequently poured onto 100 mL of 
an aqueous PVA solution (0.1%) and maintained under constant stirring for 3h to allow MSs 
hardening. After that, the MSs were washed, filtered, freeze-dried, and kept at -20 ºC indry 
conditions until used. Non-loaded PLGA MSs (blank microspheres) were prepared using the same 
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protocol without including spironolactore. Loaded and unloaded microspheres will be named as 
“Spiro-MSs” and “NL-MSs” hereby. 
 
Microsphere characterization  
Production yield percentage (PY%). The PY% was calculated as the percentage of MS weight 
divided by the total amount of PLGA and spironolactone used in the formulation process.  
PY%=
weight of microspheres
initial amount of PLGA and spironolactone
x100  
Mean particle size and particle size distribution. The mean particle size and particle size 
distribution were measured by light scattering in a Microtrac® S3500 Series Particle Size Analyzer 
(Montgomeryville, PA, USA).Before each measurement the particles were suspended in water. 
Morphological evaluation. The external morphology of MSs was evaluated by scanning electron 
microscopy (Jeol, JSM-6335F, Tokyo, Japan). Before each determination, particles were gold sputter-
coated. 
Spironolactone quantification. Spironolactone was quantified by HPLCconsisting of two Waters 
Millipore 510 pumps, autosampler Waters 712DWSP, Waters 490E UV/Vis detector. Analyses were 
performed using a 25 cm x 5 mm reverse-phase C18 5-µm column (Tracer Exctrasil ODS2, 
Teknokroma) preceded by a guard cartridge SEA 18, 100 mm x 4.0 mm (Teknokroma). The mobile 
phase was composed by methanol:water 67:33 v/v at a flow rate of 1.0 mL/min. The injection 
volume was 20 µL. UV detection of the spironolactone was carried out at 238 nm. 
Encapsulation efficiency. Spironolactone loading in the microspheres was determined as follows: 
an amount of MSs(5 mg)was initially dissolved in methylene chloride (1 mL) , PLGA was precipitated 
by the addition of ethanol (4 mL), mixed and centrifuged(8500g; 5 min). Then, the supernatant was 
recovered and filtered (0.22 µm) for drug quantification by HPLC. 
In vitro release studies. Samples (n=18) were prepared by suspending spironolactone-loaded 
MSs (5 mg) in 1.8 mL of medium (Isotonic phosphate buffered saline pH 7.4 with the addition of 
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NaCl). Samples were maintained under a constant agitation speed of 100 rpm (Clifton Shaking Bath 
NE5, Nikel Electro Ldt, Avon, UK) at 37ºC. Sampling was performed at 4, 7, 11, 14, 18, 21, 25, 28 and 
31 days of incubation. At each time point MSs suspensions were centrifuged (18,000 rpm; 3 min; 
20ºC). Two of the samples including the solid particles were recovered, frozen and freeze-dried. The 
obtained powders were treated using the same method described for encapsulation efficiency to 
determine the amount of spironolactone still remaining in the particles.The rest of the supernatants 
were removed and replaced by the same volume of fresh medium, to continue the release test. The 
amount of released spironolactone was calculated as the difference between the initial content and 
the actual content at each time point. 
 
Intravitreous injection of microspheres in rat eyes 
Suspensions of 5 µL containing either 0.5 mg of PLGA MSs (high amount) with a total dose of 53 µg of 
spironolactone, or 0.1 mg of PLGA MSs (low amount) containing a total dose of 10.6 µg 
spironolactone were injected in the rat vitreous. Particles were always suspended in NaCl 0.9%. 
Control rat eyes were injected with non-loaded MSs (0.5 mg or 0.1 mg) suspended in 0.9% NaCl and 
also 0.9% NaCl alone. 
 
In vivo and ex vivotolerance analysisof blank and spironolactone-loaded PLGA microspheres 
Electroretinogram 
Electroretinograms (ERG) were performed before and 4 weeks after IVT using VisioSystem device 
(SiemBiomedicale, Nimes, France). Animals were dark-adapted overnight. Scotopic ERG was 
performed in the dark with light intensities of flashes ranging from 0.0003 to 10 cd.s/m 2. For each 
intensity, the average response to 5 flashes at a frequency of 0.5 Hz was recorded. For photopic 
recordings, animals were light-adapted for 5 min with a background light of 25 cd/m2, and then the 
response following a single light flash of 10 cd.s/m2 was recorded. 
Optical coherence tomography 
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Thein vivo analysis of rat retina was performed at day3, one week and 4 weeks after IVT using 
spectral domain optical coherence tomography (SD-OCT, Spectralis™ device) adapted for small 
animal eyes [27]. Scans of intravitreous MSs and underling retina were taken. Each two-dimensional 
B-scan recorded at 30° field-of-view consisted of 1536 A-scans with an optical resolution reaching 
3.5μm. 
Four weeks after IVT, animals were sacrificed, eyes were enucleated and prepared for histology, 
immunofluorescence and quantitative PCR analyses.  
Histology 
Enucleated eyes were fixed in 4% paraformaldehyde (PFA) for 2h at room temperature and 
dehydrated in a graded alcohol series (70%, 95% and 100%) and embedded in historesin. Fivem 
sectionsstained with toluidine blue. The morphology and pathological modifications of ocular tissues 
were examined under a light microscope (DM5500B, Leica, Nanterre, France).  
Immunohistochemistry 
After fixed in 4% PFA for 2 h, eyes were snap frozen in Tissue-Tek OCT-compound (Bayer Diagnostics, 
Puteaux, France). Cryostat sections (10 µm) of rat eyes were washed and permeabilized with 0.1% 
Triton X-100 for 30 min. Unspecific binding sites were blocked with 5% normal goat serum for 1 h. 
The sections were then incubated with primary antibodies for 1 h at room temperature, washed in 
PBS, and further incubated with secondary antibodies for 1 h. After washing, slides were stained for 5 
min with 4’,6-Diamidino-2-Phenyl-Indole (DAPI, 1:3000), washed again, and mounted with gel mount. 
Control sections were stained without primary antibodies. Images were taken using a fluorescence 
microscope (Olympus BX51, Rungis, France) equipped with a CCD camera (Olympus DP70). The 
following antibodies were used: rabbit anti-glial fibrillary acidic protein (GFAP, 1:100, Dako, Trappes, 
France), rabbit anti-ionized calcium binding adaptor molecule-1 (anti-IBA1; 1:400, Wako Richmond, 
USA) and Alexa Fluor 488-coupled goat anti-rabbit IgG (1:200, Molecular Probes, Leiden, 
Netherlands). To quantify activated macrophages/microglial cells, all round IBA-1 positive cells were 
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counted on entire ocular cross sections at the optic nerve level. Four sections per eye  were 
quantified (n=4 rats in high and n=5 in low amount MSs groups). 
TUNEL assay 
For the TUNEL assay, rat eyes were snap frozen in Tissue-Tek OCT-compound. Eye cryosections were 
fixed with methanol/acetic acid for 20 min at room temperature, then washed in PBS, and 
permeabilized with 0.1% (w/v) sodium citrate/0.1% (v/v) Triton X-100 in water for 2 min at -4ºC. 
After washing with PBS, sections were incubated for 1 h with 50 µL of terminal 
deoxynucleotidyltransferase (TUNEL; Roche Diagnostics, Mannheim, Germany) reaction mixture at 
37 °C and counterstained with DAPI.  
Reverse Transcription and Real-Time PCR 
Total RNA was isolated from rat retinas using RNeasyPlusMini Kit (Qiagen,Courtaboeuf, France). First-
strand cDNA was synthesized using random primers (Invitrogen, CergyPontoise, France) and 
superscript II reverse transcriptase (Invitrogen). Transcript levels of neutrophil gelatinase-associated 
lipocalin (NGAL), NADPH oxidase subunit 2 (NOX2), chemokine ligand 2 (CCL2) and intercellular 
adhesion molecule-1 (ICAM-1)were analyzed by real-time PCR performed in 7500 Real-Time PCR 
System (Applied Biosystems, Foster City, CA, USA) with SYBR® Green (Invitrogen) detection. The 18S 
and hypoxanthine phosphoribosyltransferase 1 (HPRT1) were used as internal controls. The 
sequences of primers: NGAL, forward, 5’-TCACCCTGTACGGAAGAACC-3’, reverse, 5’-
GGTGGGAACAGAGAAAACGA-3’; NOX2, forward, 5’-GCCTCCATTCTCAAGTCTGTCT-3’, reverse, 5’-
GGAAGTTGGCATTGTTTCTTTC-3’; CCL2, forward, 5’-CCTGCTGCTACTCATTCAC-3’, reverse, 5’-
TCTCACTTGGTTCTGGTCC-3’; ICAM, forward, 5’-AGAAGGACTGCTTGGGGAA-3’; reverse, 5’-
CCTCTGGCGGTAATAGGTG-3’; 18S, forward, 5’-TGCAATTATTCCCCATGAACG-3’, reverse, 5’-
GCTTATGACCCGCACTTACTGG-3’; HPRT1, forward, 5’-GCGAAAGTGGAAAAGCCAAGT-3’, reverse, 5’-
GCCACATCAACAGGACTCTTGTAG-3’. Delta cycle threshold calculation was used for relative 
quantification of results. 
Statistics 
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Data are provided as mean ± SEM. Comparison between groups was performed using 1- or 2-way 
ANOVA followed by Bonferroni test (GraphPad Prism 5; GraphPad Software). A P value less than 0.05 
was considered statistically significant.  
 
Results 
Soludactonedid not alter the morphology nor the function of the rat retina 
One week after IVT, eye fundus and OCT sections showed that soludactonesolution(Figure 1A) did 
not induce retinal damage as compared to saline control (Figure 1B) around the optic nerve, as well 
as in the other quadrant of the retina. No retinal inflammation or edema was noticed. Histological 
analyses confirmed in vivo findings. There was no inflammation observed near the optic nerve or in 
irido-corneal angles either in soludactone-injected (Figure 2B) or in sham-injected rat eyes (Figure 
2A). Retinal structure near the IVT site was preserved. Histology also highlighted the healing process 
at the IVT site, in the control and soludactone groups. Scotopic and photopic ERGs showed no 
difference in photoreceptor function between soludactone and control groups (Figure 3) suggesting 
that intravitreous soludactone does not affect the retinal function of rat eyes.  
 
Figure 1. Fundus and optical coherence tomography (OCT) examination of the rat retinas one week 
after soludactone intravitreous injection (B) compared to saline control (A). (A1, B1)  Eye fundi show 
no difference between soludactone-injected and sham-injected eyes. (A2, B2) Infrared images of the 
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eye fundus: each green line corresponds to the frame (F) of the OCT sections in (A3, B3).n=4 rats per 
group. Scale bars: 200 µm. 
 
 
Figure 2.Histology of rat eyes one week after soludactone injection (B) compared tosaline (A).No 
inflammatory cell is observed near the optic nerve or in the iridocorneal angle in both groups. The 
neuroretina maintains laminated structure in both soludactone-injected and saline-injected rat eyes. 
Wound healing process is observed at the IVT sites in both groups. GCL, Ganglion Cell Layer; INL, 
Inner Nuclear Layer; IPL, Inner Plexiform Layer; ONL, Outer Nuclear Layer; OPL, Outer Plexiform 
Layer.n=4 rats per group. 
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Figure 3.Electroretinogramsof rat eyes one week after soludactone IVT compared to saline 
injection.Scotopica-wave amplitude (A) and b-wave (B) amplitude show no significant difference 
between control and soludactone-injected eyes. Photopic ERG also finds no difference in b-wave 
amplitude between 2 groups. n=8 eyes/group. 
 
Spironolactone has a short intravitreal half-life in the human vitreous 
In vitro kinetics of spironolactone showed a decrease of around 30% of spironolactone after 60 
minutes in contact with human vitreous. In vivo kinetics of spironolactone injected in the vitreous of 
the rat eye showed that at 15 minutes after IVT, the intravitrealconcentration of spironolactone 
corresponded to 90% of injected dose but at 60 minutes only half of the amount of spironolactone 
wasleft in the vitreous. These findings suggest that spironolactone is relatively stable, but eliminated 
rapidly from the vitreous. After systemic administration, no spironolactone could be detected in 
ocular media at any time point indicating that spironolactone does not cross the blood-retinal barrier 
(results not shown). 
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Characterizationof spironolactone-loaded PLGA microspheres 
The production yield resulted56.9%, with a mean particle size of17.5 ± 5.0μm. SEM 
picturesrevealedMSs with spherical shapeand absence of irregularities on their surface(Figure 4A). 
The amount of spironolactone in the MSs resulted105.9μgspironolactone/mg MSs (encapsulation 
efficacy of 63.5%).  
The in vitro release study showed a sustained release of the spironolactone at a rate of 2.87 
μgspironolactone/mg MSs/day (Figure 4B) during the 31-day study. According to this,high amount 
Spiro-MSs released approximately 1.434μgspironolactone/day, while low amount Spiro-MSs released 
0.287 µg spironolactone/day. As the microencapsulated drug remains in its solid state until it is 
released from microspheres, spironolactone degradation at this point is not expected. 
 
Figure 4. Scanning electron microscopy picture of spironolactone-loaded microspheres (MSs) (A) 
and cumulative in vitro release of spironolactone (μg Spiro/mg MSs and %) over 31days from 
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spironolactone-loaded PLGA MSs (B). Release media: PBS (pH 7.4)isotonized with NaCl. 
 
Spironolactone-loaded PLGA MSs did not induce change in rat retinal structure 
OCT showed that at day3 after IVT, MSs tended to aggregate in the vitreous with the underlying 
retina maintained its normal structure in both NL-MSs and Spiro-MSs groups (Figure5A and B). The 
amount of visible MSs diminished thereafter from 1 week to 4 weeks (Figure 5C-F). At 4 weeks after 
IVT, MSs are still present in the vitreous (Figure 5E and F). No inflammation or change in retinal 
lamination was observed in vivo at any assayed time (Figure 5C-F).   
In all groups (NL-MSs and Spiro-MSs) even with high amount of microspheres (Figures 6B,6C, 6E and 
6F) histology showed that no inflammation occurs in the ciliary body or in the retina four weeks after 
IVT, as compared to NaCl-injected control rat eyes (Figure 6A and D). The retina maintained its 
lamination structure (Figure 6D-F). Morphology of eyes injected with low amount of MSs showed the 
same intact ocular structure (not shown). 
TUNEL test showed apoptotic corneal epithelial cells as positive control (arrows in Figure 7A). In 
either high amount (Figure 7B and C) or low amount of MSs groups (not shown), we did not observe 
TUNEL-positive cells in the rat retina except for the site of the IVT. 
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Figure 5. Optical coherence tomography (OCT) examination of the rat eyes injected with non-
loaded (NL-MSs) and spironolactone-loaded PLGA microspheres (Spiro-MSs). At day3 after IVT, MSs 
tend to aggregate in the vitreous in both NL-MSs (A) and Spiro-MSs groups (B). MSs decrease from 1 
week (C and D) to 4 weeks (E-F) and scattered at 4 weeks after IVT (E and F). The underlying retina 
maintains its normal structure at each time point (A-F) in both groups. Arrows indicate microspheres. 
Scale bars: 200 µm. 
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Figure 6. Histology of the rat ciliary body and retina 4 weeks after IVT of high amount of PLGA 
microspheres (MSs).The eyes injected with non-loaded (NL-MSs) or spironolactone-loaded PLGA 
microspheres (Spiro-MSs) show intact ciliary body (CC, B and C) and retinal structure (E and F) 
compared to saline-injected eyes (A and D). No inflammatory cell is observed. GCL, ganglion cell layer; 
IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform layer; ONL, outer nuclear 
layer; RPE, retinal pigment epithelium. n=4 rats per group, scale bars: 50 µm. 
 
 
Figure 7. TUNEL assay of rat retina 4 weeks after IVT of high amount ofPLGAmicrospheres. TUNEL 
positive corneal epithelial cells (green) serve as positive control (arrows in A). No TUNEL positive cell 
is observed in the retina of rat eyes injected with either non-loaded PLGA microspheres (NL-MSs) or 
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spironolactone-loaded microspheres (Spiro-MSs). EP, corneal epithelium; Endo, corneal endothelium; 
GCL, ganglion cell layer; INL, inner nuclear layer; ONL, outer nuclear layer. n=4 rats per group, scale 
bars: 50 µm. 
 
High amount but not low amount of PLGA microspheres may induce retinal stress 
The amount of injected MSs resulted in different retinal responses. GFAP labels astrocytes and end 
feet of retinal Müller glial cells (RMG) in saline-injected rat eyes are shown in Figure 8A. Both high 
amount of NL-MSs and Spiro-MSs enhanced GFAP fluorescence in activated RMG extending up to 
outer limiting membrane (Figure 8B and C). Low amount of NL-MSs and Spiro-MSs induced only a 
moderate activation of RMG, GFAP staining was limited in the inner retina (Figure 8D and E).  
Macrophages and microglial cells were immunolabeled by anti-IBA1 antibody. Activation of microglia 
induces modification of its shape from ramified multidirectional extensions to polarized dendrites 
and then to round amoeboid cells. In saline-injected rat eyes, macrophages/microglial cells maintain 
their inactive ramified shape (Figure 9A). In high amount NL-MSs and Spiro-MSs groups, some 
macrophages/microglial cells became rounded and activated (Figure 9B and C, arrows), in eyes 
injected with low amount NL-MSs or Spiro-MSs, only a few round amoeboid cells were observed 
(Figure 9E and F). Quantification of IBA1 positive cells showed that the number of activated 
macrophage/microglia was significantly decreased in low amounts ofMSs-injected eyes. No 
difference was observed between NL-MSs and Spiro-MSs (Figure 9D). 
These results suggest that high amount ofMSs injected in the vitreouscan induce glial activation, 
related to PLGA and not specifically to spironolactone, as no additional toxicity was observed in 
spironolactone-loaded MSs as compared to NL MSs. 
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Figure 8. GFAP immunostaining in the rat retina 4 weeks after IVT of spironolactone-loaded (Spiro-
MSs) and non-loaded PLGA microspheres (NL-MSs).GFAP (in red) labels astrocytes and end feet of 
retinal Müller glial cells (RMG) in saline-injected rat eyes (A). Both high amount NL-MSs (B) and Spiro-
MSs (C) enhance GFAP fluorescence in activated RMG extending up to outer limiting membrane 
(OLM). GFAP staining is limited in the inner retina in the retina of rat eyes injected with low amount 
MSs (D and E). There is no difference between NL-MSs and Spiro-MSs. GCL, ganglion cell layer; INL, 
inner nuclear layer; ONL, outer nuclear layer. n=4 rats in high amount groups and 5 rats in low 
amount groups. Scale bars: 50 µm. 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
 
Figure 9. IBA-1 immunolabeling of macrophages and microglial cells in rat retina 4 weeks after IVT 
of spironolactone-loaded (Spiro-MSs) and non-loaded PLGA microspheres (NL-MSs). In saline-
injected rat eyes, macrophages/microglial cells maintain their inactive ramified shape (A). In high 
amount NL-MSs (B) and Spiro-MSs groups (C), some macrophages/microglial cells become rounded 
and activated (arrows). In eyes injected with low amount NL-MSs(E) or Spiro-MSs (F), only a few 
round amoeboid cells are observed (E and F). Quantification of IBA1 positive cells showsa significant 
decrease in activated macrophage/microglia in low amount MSs-injected eyes. No difference was 
observed between NL-MSs and Spiro-MSs (D). GCL, ganglion cell layer; INL, inner nuclear layer; ONL, 
outer nuclear layer. n=4 rats in high amount groups and 5 rats in low amount groups. ***, P < 0.001. 
Scale bars: 50 µm. 
High amount but not low amount of PLGA microspheres alter rat retinal function  
Scotopic ERGs showed a significant reduction of a- and b-wave amplitude in eyes injected with high 
amountMSs (both NL- and Spiro-MSs) at intensities from 0.3 to 10 cd.s.m-2, while low amountMSs did 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
 
not decrease the amplitude of both a and b waves, suggesting also that high dose but not low dose 
MSs could affect photoreceptor function (Figure 10). No significant difference was observed in 
photopic ERGs after IVT of high or low amountMSs (Figure 11). There was no difference between NL- 
and Spiro-loaded MSs on scotopic and photopic ERGs. ERG findings suggest that IVT of high 
amountMSs could be harmful for retinal function, while injections with low amountMSsresulted safe. 
No additional change in retinal function was observed for spironolactone released from MSs. 
 
Figure 10. Scotopicelectroretinograms (ERGs) of rat eyes injected with spironolactone-loaded 
(Spiro-MSs) and non-loaded PLGA microspheres (NL-MSs). While low amount MSs do not decrease 
the amplitude of both a and b waves, high amount MSs reduce significantly scotopic a-wave 
amplitude at intensities from 0.3 to 3 cd.s.m-2 as well as b-wave amplitude at intensities from 0.3 to 
10 cd.s.m-2.There is no difference between NL- and Spiro-loaded MSs on scotopic ERGs. n=4-8 rats 
per group. *, P < 0.05; **, P < 0.01. 
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Figure 11. Photopicelectroretinograms (ERGs) of rat eyes injected with spironolactone-loaded 
(Spiro-MSs) and non-loaded PLGA microspheres (NL-MSs). No significant difference was observed in 
photopic ERGs after IVT of high or low amount MSs. n=4-8 rats per group. 
 
Spironolactone released from intravitreous PLGA microspheres has biological effects in the rat 
retina 
After intraocular injection of spironolactone-loaded MSs, we evaluated the effects on known biologic 
spironolactone regulated targets[28-30] to ensure that the released spironolactone was active in the 
retina.  
Quantitative PCR was thus performed using rat retinas 1 month after IVT. We found that the 
transcription of spironolactone target genes, like NGAL, NOX2, CCL2 and ICAM-1, was down-
regulated (Figure 12), suggesting that spironolactone releasedfrom PLGA MSsreached the retina and 
exerted biological effects in the rat retinas.  
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Figure 12. Quantitative PCR of the neuroretina of rat eyes injected with low amount of PLGA 
microspheres. Spironolactone released from microspheres (Spiro-MSs) decreases the transcripts of 
neutrophil gelatinase associated lipocalin (NGAL), NADPH oxidase subunit 2 (NOX2), chemokine 
ligand 2 (CCL2) and intercellular adhesion molecule-1 (ICAM-1) in rat neuroretina compared to non-
loaded microspheres (NL-MSs). n=5 rats per group. *, P < 0.05. 
 
Discussion 
While the pharmacokinetic and pharmacodynamic properties of MR antagonists (MRA), and their 
therapeutic effects on cardiovascular disease and systemic adverse effects are well-documented, 
little is known about the pharmacology of MRA in the eye. We recently demonstrated that whist 
MRA can exert beneficial anatomic and functional results in patients with CSCR,[15, 18, 31, 32] a 
long-term treatment with MRA is required in long-lasting chronic forms of the disease [18, 33]. The 
exact ocular bioavailability of spironolactone after oral administration was not known and a possible 
reduction of its ocular penetration together with a restoration of the blood-retinal barriers is 
suspected.  In a preliminary experiment, we found that, after intravenous injection of spironolactone 
in rats without blood-retinal barrier breakdown, spironolactone and its metabolites were below 
detectable levels in the vitreous suggesting that the clinical observed effect could result partly from 
the effects on the choroidal vessels which are not protected by retinal barriers (reduced thickness 
and vasodilation) but also probably from spironolactone penetration through RPE barrier breakdown, 
occurring in acute episodes and in chronic forms of the diseases. We thus hypothesize that optimized 
efficacy and systemic tolerance of spironolactone could be achieved by the direct intraocular 
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administration of spironolactone. Amongst MRA, spironolactone was selected for ocular 
formulations because eplerenone has a 40-fold lower affinity for the MR but higher selectivity, 
reducing systemic hormonal effects, which cannot be feared after intraocular injection. We have first 
evaluated the ocular tolerance of the only commercial intravenous preparation of potassium 
canrenoate (Soludactone®, Pfizer), that is the active metabolite of the prodrug spironolactone for 
potential further clinical use. At a clinically relevant dose (10 µM) which corresponds to minimal 
effective concentration blocking the mineralocorticoid activity in rat eyes [9, 14], Soludactone did not 
induce morphological and functional alterations in the rat retina, suggesting the safety of its 
formulation. However, spironolactone and canrenone have very short half -life in the vitreous in vivo, 
requiring frequent administrations to maintain therapeutic concentrations in the target site. For this 
reason, the use of an intraocular drug delivery systemable to release the active substance for long 
term would result of great interest in the clinical practice. 
Biodegradable MSs for intraocular drug delivery have the advantage that they can release the drug 
over time with one single intravitreous injection, having the same effect as multiple injections. 
Among the polymers used for intraocular drug delivery, PLGA are the most employed and it is 
approved by FDA and European Medicines Agency (EMA) for clinical use [34]. PLGA MSs 
incorporating active substances have been evaluated in experimental models of uveitis [35], diabetic 
retinopathy [36], glaucoma [37, 38], photoreceptor degeneration[39, 40], choroidal 
neovascularization [41] and regenerative medicine [42]. Furthermore, Ozurdex®(Allergan), 
intravitreous implant composed of PLGA releasing dexamethasone, has been approved to treat 
macular edema and non-infectious uveitis[43].  
In our study, spiro-MSs showed sustained in vitro release of spironolactone for 31 days due to the 
fact that a PLGA 50:50 (50% lactide and 50% glycolide) was used, allowing a relatively rapid 
degradation [22]. However, if desired, the degradation rate can be modulated by modifying the 
PLA:PGA ratio as well as the molecular weight of the polymer. Also the degradation rate of D- or L-
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PLA, DL-PLA and PGA is slower than PLGA, making it possible to select the most adequate polymer to 
prepare the particles [40].  
As previously described, MSs have the tendency to aggregate several days after IVT in small animals 
[22, 44], a phenomenon that we also observed in the present study. Among the clinical signs, 
inflammation can occur in early stages after IVT of PLGA MSs. These signs have been described to be 
similar to the observed for sutures and disappear 2-4 weeks after administration. Giordano et al 
explained as a non-progressive foreign body reaction [44].The clinical follow-up preformed using SD-
OCT has shown a continuous degradation of microspheres from injection to the 4th week. It is 
therefore unlikely that additional inflammatory reaction would be observed at later time points. 
Previous experiments have shown that no inflammatory reaction occurred in rabbits at the end of 
PLA/PLGA microspheres degradation after intravitreal injection, except for activation of retinal glial 
Müller cells, similar to our observations[44].  
In our experimental conditions, no retinal and choroidal damage were observed 1 month after 
administration. In human, the special concern is related to the risk of visual impairment after IVT of 
MSs. This clinical issue has been previously evaluated in a tolerance study, in which sustained-release 
triamcinolone MSs system (RETAAC) was injected in human eyes. Authors reported a tendency of the 
MSs to aggregate and condensate at the site of the injection leaving a free visual axis. In the same 
study, no inflammation was observed after MSs injection, although it should be taken into account 
that, the anti-inflammatory drug could attenuate the inflammatory reaction [45]. In the present 
study, high amount of PLGA MSs (0.5 mg) resulting in an intravitreal concentration of 10 mg/mL lead 
to retinal macro and microglial reactions. However, it did not alter retinal structure, neither induce 
apoptosis in retinal neuronal cells. A reduced scotopic ERGs was also observed, suggesting 
photoreceptor dysfunction. On the contrary, low concentrations of PLGA MSs (intravitreal 
concentration 2 mg/mL) appear well tolerated and did not alter retinal function, findings consistent 
with previous studies describing the safety of low concentration intravitreal PLGA MSs in rabbit eyes 
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[24, 44]. In larger eyes with higher vitreous cavity, reduced inflammatory reaction is expected as 
observed with PLGA rods. The amount of spironolactone in vitro released from low amount of MSs 
resulted sufficient to inhibit mineralocorticoid activity in the retina and choroid [9, 11].  
Despite the undeniable interest of performing the in vivo pharmacokinetic study of the Spiro-MSs, it 
was technically not possible due to the small volume of intraocular fluid in rats and spironolactone 
concentrations below the detection limit of the assay. Biological effects were instead measured at 
one month after Spiro-MSs administration to evaluate whether spironolactone was still present in 
the retina. In eyes receiving Spiro-MSs, we could identify known MR- regulated targets, reflecting 
effects of spironolactone in the retina. Amongst the regulated targets, oxidative stress and 
inflammation were reduced which could have contributed to the good tolerance of Spiro-
Ms.Although spironolactone PK profile observed in vitro cannot be simply extrapolated to the in vivo 
release of spironolactone from MS, it gives the information that the kinetic profile of spironolactone 
from PLGA microspheres (>1 month) is compatible with clinical use. The rat vitreous being different 
from the human vitreous and vitreous drug levels not being an imperfect reflect of retinal drug levels, 
we have chosen not to perform release kinetic in the rat (that has a very small vitreous volume, i.e. 
around 30µl) but rather to analyze in one hand the stability of spironolactone in human vitreous and 
on the other hand to test whether biological effect of spironolactone was still observed in the retina 
at 4 weeks. Our results have shown that indeed, known spironolactone molecular targets were still 
regulated in the neuroretina at 4 weeks. 
This is the first study evaluating the ocular tolerance of MRA in solution and spironolactone loaded 
PLGA MSs. It demonstrates that intravitreous injection of soludactone alone did not affect the retinal 
morphology and function. PLGA MSs allows a sustained release of spironolactone. High intravitreal 
concentration of PLGA MSs (10 mg/mL) unloaded and loaded with spironolactone induce somehow 
retinal stress and photoreceptor dysfunction in rats. However, MSs concentration of 2 mg/mL 
(unloaded and loaded with spironolactone) in rat eyes showed excellent morphologic and functional 
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tolerance and could be a safe therapeutic choice for chorioretinal disorders in which illicit MR 
activation could be pathogenic. Optimized formulations with longer release profile could benefit to 
patients with severe CSCR forms requiring long-term ocular MR antagonism, whilst suppressing 
potential side-effects. 
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